P1.080. Dynamic ctDNA Profiling Predicts Pathological Complete Response and Identifies Pseudoprogression in ESCC Receiving Neoadjuvant Immunochemotherapy

Clicks: 24
ID: 326142
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #60 of 453 articles by views in diseases of the esophagus : official journal of the international society for diseases of the esophagus

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 453 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Topic Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies Background The integration of anti-PD-1 antibody therapy with chemotherapy has shown promising results in the neoadjuvant treatment of locally advanced esophageal squamous cell carcinoma. Conventional imaging may not fully capture immunotherapy effects due to unconventional response patterns like pseudoprogression. Methods We enrolled 23 esophageal squamous cell carcinoma patients receiving neoadjuvant immunochemotherapy and surgery. Plasma was collected pre- and post-treatment for ctDNA analysis. Baseline tumor biopsies were used to build ctDNA panels and assess tissue TMB via targeted sequencing. ctDNA positivity was defined by matched somatic variants; TMB was calculated as total coding mutations per sample. Results At baseline, ctDNA was detected in 87% of patients. The results demonstrated that the dynamic change patterns of ctDNA levels were significantly associated with pCR rates. Specifically, patients with undetectable ctDNA post-ICT had a significantly higher pCR rate compared to ctDNA-positive patients (71.4% vs. 12.5%, p<0.05). ctDNA dynamics stratified patients into distinct response groups, with those remaining ctDNA-negative throughout treatment exhibiting had a higher risk of pCR. In contrast, tissue TMB and PD-L1 expression were not significantly associated with pCR. Furthermore, ctDNA was effective in identifying pseudoprogression, where radiologic progression was contradicted by decreasing ctDNA levels and confirmed pCR postoperatively. Conclusion Our results suggest that ctDNA may serve as a potential biomarker for assessing treatment response in patients with esophageal squamous cell carcinoma undergoing neoadjuvant Immunochemotherapy. Further research could elucidate the specific ctDNA signatures that correlate with therapeutic efficacy and metastatic spread, enhancing personalized treatment strategies for esophageal squamous cell carcinoma.
Reference Key
openalex_W7203989284 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Jianfeng Zhou, Yushang Yang, Yong Yuan, Zewen Wang
Are you one of these authors? Claim your profile
Journal diseases of the esophagus : official journal of the international society for diseases of the esophagus
Year 2026
DOI
10.1093/dote/doag077.228
URL
https://doi.org/10.1093/dote/doag077.228
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.